IND-Enabling Preclinical Studies of 2DG for Prevention of Post-Traumatic Epilepsy in Plasticity-Susceptible Rats
Post-traumatic epilepsy is a major cause of ongoing and progressive morbidity in survivors of traumatic brain injury (TBI) which afflicts as many as 1.7 million people in the US each year. Overall, PTE accounts for nearly 20% of all symptomatic epilepsies in the general population, and is the most common cause of acquired epilepsies. This project is addressing this significant need by determining if administration of 2DG, a novel sugar analogue that blocks sugar metabolism, at the time of TBI reduces orprevents later development of post-traumatic epilepsy. Successful completion of this project will enable rapid advance of 2DG into clinical trials to reduce or prevent post-traumatic epilepsy, which would be an unprecedented advance toward the goal of “no seizures, no side effects” by preventing this most common cause of acquired epilepsy.